2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cavarape, A. Articles by Endlich, K. Search for Related Content PubMed PubMed Citation Articles by Cavarape, A. Articles by Endlich, K.

Rho-Kinase Inhibition Blunts Renal Vasoconstriction Induced by Distinct Signaling Pathways In Vivo

Alessandro Cavarape^*, Nicole Endlich, Roberta Assaloni^*, Ettore Bartoli, Michael Steinhausen, Niranjan Parekh and Karlhans Endlich

*Department of Experimental and Clinical Pathology and Medicine (DPMSC), University of Udine, Udine, Italy; Department of Anatomy and Cell Biology, University of Heidelberg, Heidelberg, Germany; Department of Clinical Pathology and Medicine, University of Piemonte Orientale, Novara, Italy; and Department of Physiology and Pathophysiology, University of Heidelberg, Heidelberg, Germany.

Correspondence to Dr. Alessandro Cavarape, Department of Experimental and Clinical Pathology and Medicine (DPMSC), Chair of Internal Medicine, Piazza S. Maria della Misericordia, 1, 33100 Udine, Italy. Phone: 39-0432-559815; Fax: 39-0432-42097;

ABSTRACT. In addition to intracellular calcium, which activates myosin light chain (MLC) kinase, MLC phosphorylation and hence contraction is importantly regulated by MLC phosphatase (MLCP). Recent evidence suggests that distinct signaling cascades of vasoactive hormones interact with the Rho/Rho kinase (ROK) pathway, affecting the activity of MLCP. The present study measured the impact of ROK inhibition on vascular F-actin distribution and on vasoconstriction induced by activation/inhibition of distinct signaling pathways in vivo in the microcirculation of the split hydronephrotic rat kidney. Local application of the ROK inhibitors Y-27632 or HA-1077 induced marked dilation of pre- and postglomerular vessels. Activation of phospholipase C with the endothelin ET_B agonist IRL 1620, inhibition of soluble guanylyl cyclase with 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ), or inhibition of adenylyl cyclase with the adenosine A₁ agonist N⁶-cyclopentyladenosine (CPA) reduced glomerular blood flow (GBF) by about 50% through vasoconstriction at different vascular levels. ROK inhibition with Y-27632 or HA-1077, but not protein kinase C inhibition with Ro 31-8220, blunted ET_B-induced vasoconstriction. Furthermore, the reduction of GBF and of vascular diameters in response to ODQ or CPA were abolished by pretreatment with Y-27632. ROK inhibitors prevented constriction of preglomerular vessels and of efferent arterioles with equal effectiveness. Confocal microscopy demonstrated that Y-27632 did not change F-actin content and distribution in renal vessels. The results suggest that ROK inhibition might be considered as a potent treatment of renal vasoconstriction, because it interferes with constriction induced by distinct signaling pathways in renal vessels without affecting F-actin structure. E-mail: alessandro.cavarape@dpmsc.uniud.it

This article has been cited by other articles:

				E. Bussemaker, F. Pistrosch, S. Forster, K. Herbrig, P. Gross, J. Passauer, and R. P. Brandes Rho kinase contributes to basal vascular tone in humans: role of endothelium-derived nitric oxide Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H541 - H547. [Abstract] [Full Text] [PDF]

				W. A. Cupples and B. Braam Assessment of renal autoregulation Am J Physiol Renal Physiol, April 1, 2007; 292(4): F1105 - F1123. [Abstract] [Full Text] [PDF]

				K. Hayashi, S. Wakino, N. Sugano, Y. Ozawa, K. Homma, and T. Saruta Ca2+ Channel Subtypes and Pharmacology in the Kidney Circ. Res., February 16, 2007; 100(3): 342 - 353. [Abstract] [Full Text] [PDF]

				S. K. Fellner and W. Arendshorst Endothelin-A and -B receptors, superoxide, and Ca2+ signaling in afferent arterioles Am J Physiol Renal Physiol, January 1, 2007; 292(1): F175 - F184. [Abstract] [Full Text] [PDF]

				J. Song, C. K. Kost Jr., and D. S. Martin Androgens potentiate renal vascular responses to angiotensin II via amplification of the Rho kinase signaling pathway Cardiovasc Res, December 1, 2006; 72(3): 456 - 463. [Abstract] [Full Text] [PDF]

				Y. Shi, X. Wang, K. H. Chon, and W. A. Cupples Tubuloglomerular feedback-dependent modulation of renal myogenic autoregulation by nitric oxide Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2006; 290(4): R982 - R991. [Abstract] [Full Text] [PDF]

				S. K. Fellner and L. Parker Endothelin-1, superoxide and adeninediphosphate ribose cyclase in shark vascular smooth muscle J. Exp. Biol., March 15, 2005; 208(6): 1045 - 1052. [Abstract] [Full Text] [PDF]

				S. K. Fellner and L. A. Parker Endothelin B receptor Ca2+ signaling in shark vascular smooth muscle: participation of inositol trisphosphate and ryanodine receptors J. Exp. Biol., September 1, 2004; 207(19): 3411 - 3417. [Abstract] [Full Text] [PDF]

				M. Trovati and F. Cavalot Optimization of Hypolipidemic and Antiplatelet Treatment in the Diabetic Patient with Renal Disease J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S12 - 20. [Abstract] [Full Text]

				A. Sorokin and D. E. Kohan Physiology and pathology of endothelin-1 in renal mesangium Am J Physiol Renal Physiol, October 1, 2003; 285(4): F579 - F589. [Abstract] [Full Text] [PDF]

				C. C. Sharpe and B. M. Hendry Signaling: Focus on Rho in Renal Disease J. Am. Soc. Nephrol., January 1, 2003; 14(1): 261 - 264. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673